Literature DB >> 2165836

Responses of rat substantia nigra compacta neurones to L-DOPA.

N B Mercuri1, P Calabresi, G Bernardi.   

Abstract

1. The electrophysiological actions of L-DOPA were studied on substantia nigra dopamine-containing neurones by use of intracellular recordings, current and voltage clamp, in vitro. 2. L-DOPA (3-300 microM), applied by superfusion, decreased the spontaneous firing activity of the neurones, hyperpolarized the membrane potential and produced an outward current. 3. These effects of L-DOPA were graded and were antagonized by sulpiride, a D2-receptor antagonist. 4. The L-DOPA activated membrane hyperpolarization persisted in slices exposed to tetrodotoxin while it was markedly reduced or abolished in solutions with no calcium plus cobalt (2 mM). 5. In slices treated with carbidopa, an inhibitor of the aromatic amino acid decarboxylase enzyme, the actions of L-DOPA were greatly reduced. 6. We propose that L-DOPA inhibits the firing of substantia nigra zona compacta neurones by being converted to dopamine which is then released by these cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165836      PMCID: PMC1917416          DOI: 10.1111/j.1476-5381.1990.tb15792.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Release of dopamine from dendrites in rat substantia nigra.

Authors:  L B Geffen; T M Jessell; A C Cuello; L L Iversen
Journal:  Nature       Date:  1976-03-18       Impact factor: 49.962

2.  Dopamine release in substantia nigra?

Authors:  J Korf; M Zieleman; B H Westerink
Journal:  Nature       Date:  1976-03-18       Impact factor: 49.962

3.  Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease.

Authors:  N B Mercuri; P Calabresi; G Bernardi
Journal:  Neurology       Date:  1989-08       Impact factor: 9.910

4.  Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones.

Authors:  B S Bunney; G K Aghajanian; R H Roth
Journal:  Nat New Biol       Date:  1973-09-26

Review 5.  The mechanisms of action of L-dopa in Parkinson's disease.

Authors:  O Hornykiewicz
Journal:  Life Sci       Date:  1974-10-01       Impact factor: 5.037

6.  The mechanism of amphetamine-induced inhibition of rat substantia nigra compacta neurones investigated with intracellular recording in vitro.

Authors:  N B Mercuri; P Calabresi; G Bernardi
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

7.  Two cell types in rat substantia nigra zona compacta distinguished by membrane properties and the actions of dopamine and opioids.

Authors:  M G Lacey; N B Mercuri; R A North
Journal:  J Neurosci       Date:  1989-04       Impact factor: 6.167

Review 8.  Dopamine (3-hydroxytyramine) and brain function.

Authors:  O Hornykiewicz
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

9.  L-Dopa-induced release of cerebral monoamines.

Authors:  K Y Ng; T N Chase; R W Colburn; I J Kopin
Journal:  Science       Date:  1970-10-02       Impact factor: 47.728

10.  Evidence that the substantia nigra is a site of action for L-DOPA.

Authors:  G S Robertson; H A Robertson
Journal:  Neurosci Lett       Date:  1988-06-29       Impact factor: 3.046

View more
  12 in total

1.  Firing properties of dopamine neurons in freely moving dopamine-deficient mice: effects of dopamine receptor activation and anesthesia.

Authors:  Siobhan Robinson; David M Smith; Sheri J Y Mizumori; Richard D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-18       Impact factor: 11.205

Review 2.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

3.  Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells.

Authors:  N B Mercuri; M Scarponi; A Bonci; A Siniscalchi; G Bernardi
Journal:  J Neurosci       Date:  1997-04-01       Impact factor: 6.167

4.  Dopamine selectively reduces GABA(B) transmission onto dopaminergic neurones by an unconventional presynaptic action.

Authors:  Mauro Federici; Silvia Natoli; Giorgio Bernardi; Nicola B Mercuri
Journal:  J Physiol       Date:  2002-04-01       Impact factor: 5.182

Review 5.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

Review 6.  Neurophysiology of the brain stem in Parkinson's disease.

Authors:  Cecilia Bove; R Alberto Travagli
Journal:  J Neurophysiol       Date:  2019-03-27       Impact factor: 2.714

7.  L-Dopa activates histaminergic neurons.

Authors:  Yevgenij Yanovsky; Sha Li; Boris P Klyuch; Qiaoling Yao; Patrizio Blandina; M Beatrice Passani; Jian-Sheng Lin; Helmut L Haas; Olga A Sergeeva
Journal:  J Physiol       Date:  2011-01-17       Impact factor: 5.182

8.  Presynaptic glycine receptors on GABAergic terminals facilitate discharge of dopaminergic neurons in ventral tegmental area.

Authors:  Jiang-Hong Ye; Fushun Wang; Kresimir Krnjevic; Weizhen Wang; Zhi-Gang Xiong; Jingli Zhang
Journal:  J Neurosci       Date:  2004-10-13       Impact factor: 6.167

9.  Electrophysiological effects of amineptine on neurones of the rat substantia nigra pars compacta: evidence for an inhibition of the dopamine uptake system.

Authors:  N B Mercuri; F Stratta; P Calabresi; G Bernardi
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

10.  Depression of Serotonin Synaptic Transmission by the Dopamine Precursor L-DOPA.

Authors:  Stephanie C Gantz; Erica S Levitt; Nerea Llamosas; Kim A Neve; John T Williams
Journal:  Cell Rep       Date:  2015-07-30       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.